Oncternal Therapeutics, Inc. (ONCT) earnings
ONCT earnings moved a median of -8.54% by the close. Quarterly and annual ONCT reports and results, each read against the price at its own news timestamp. Back to the ONCT overview →
11 measured ONCT earnings events.
Where these ONCT earnings landedvs 10 measured ONCT earnings reactions
| Middle 50% of ONCT earnings reactions | -9.12% to +0.69% |
|---|---|
| Median reaction (to close) | -8.54% |
| Measured reactions | 10 |
Point-in-time · zero look-ahead
Half of the 10 ONCT earnings events with a measured close landed between -9.12% and +0.69%; 40% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Oncternal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.54% | -19.88% | |
| Form 10-Q Oncternal Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -4.18% | -8.54% | |
| Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results | Press release | -4.18% | -8.54% | |
| Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results | Press release | +0.00% | -10.30% | |
| Form 10-Q Oncternal Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | — | -9.12% | |
| Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results | Press release | — | -9.12% | |
| Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results | Press release | — | — | |
| Form 10-K Oncternal Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +3.90% | |
| Form 10-Q Oncternal Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +3.92% | +0.69% | |
| Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results | Press release | +3.92% | +0.69% | |
| Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results | Press release | +1.47% | +5.88% |
Keep exploring
More ONCT: analyst actions → · SEC filings → · ONCT overview →